Literature DB >> 17139617

Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.

N-Y Cho1, B-H Kim, M Choi, E J Yoo, K C Moon, Y-M Cho, D Kim, G H Kang.   

Abstract

Promoter CpG island hypermethylation is an important carcinogenic event in prostate adenocarcinoma. Regardless of tissue type, human cancers have in common both focal CpG island hypermethylation and global genomic hypomethylation. The present study evaluated CpG island loci hypermethylation and LINE-1 and Alu repeat hypomethylation in prostate adenocarcinoma, analysed the relationship between them, and correlated these findings with clinicopathological features. We examined 179 cases of prostate adenocarcinoma and 30 cases of benign prostate hypertrophy for the methylation status of 22 CpG island loci and the methylation levels of LINE-1 and Alu repeats using methylation-specific polymerase chain reaction and combined bisulphite restriction analysis, respectively. The following 16 CpG island loci were found to display cancer-related hypermethylation: RASSF1A, GSTP1, RARB, TNFRSF10C, APC, BCL2, MDR1, ASC, TIG1, RBP1, COX2, THBS1, TNFRSF10D, CD44, p16, and RUNX3. Except for the last four CpG island loci, hypermethylation of each of the remaining 12 CpG island loci displayed a close association with one or more of the prognostic parameters (ie preoperative serum prostate specific antigen level, Gleason score sum, and clinical stage). Prostate adenocarcinoma with hypermethylation of each of ASC, COX2, RARB, TNFRSF10C, MDR1, TIG1, RBP1, NEUROG1, RASSF1A, and GSTP1 showed a significantly lower methylation level of Alu or LINE-1 than prostate adenocarcinoma without hypermethylation. In addition, hypomethylation of Alu or LINE-1 was closely associated with one or more of the above prognostic parameters. These data suggest that in tumour progression a close relationship exists between CpG island hypermethylation and the hypomethylation of repetitive elements, and that CpG island hypermethylation and DNA hypomethylation contribute to cancer progression. Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17139617     DOI: 10.1002/path.2106

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  79 in total

1.  Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells.

Authors:  Limin Shu; Tin Oo Khor; Jong-Hun Lee; Sarandeep S S Boyanapalli; Ying Huang; Tien-Yuan Wu; Constance L-L Saw; Ka-Lung Cheung; Ah-Ng Tony Kong
Journal:  AAPS J       Date:  2011-09-22       Impact factor: 4.009

Review 2.  Promoter hypermethylation in prostate cancer.

Authors:  Jong Y Park
Journal:  Cancer Control       Date:  2010-10       Impact factor: 3.302

3.  Repetitive element hypomethylation in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative Aging Study.

Authors:  Zhong-Zheng Zhu; David Sparrow; Lifang Hou; Letizia Tarantini; Valentina Bollati; Augusto A Litonjua; Antonella Zanobetti; Pantel Vokonas; Robert O Wright; Andrea Baccarelli; Joel Schwartz
Journal:  Cancer Causes Control       Date:  2010-12-25       Impact factor: 2.506

4.  Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences.

Authors:  Leonora Balaj; Ryan Lessard; Lixin Dai; Yoon-Jae Cho; Scott L Pomeroy; Xandra O Breakefield; Johan Skog
Journal:  Nat Commun       Date:  2011-02-01       Impact factor: 14.919

Review 5.  Prospects for epigenetic epidemiology.

Authors:  Debra L Foley; Jeffrey M Craig; Ruth Morley; Craig A Olsson; Craig J Olsson; Terence Dwyer; Katherine Smith; Richard Saffery
Journal:  Am J Epidemiol       Date:  2009-01-12       Impact factor: 4.897

6.  Detection of serum Alu element hypomethylation for the diagnosis and prognosis of glioma.

Authors:  Jian Chen; Mingjie Gong; Shendong Lu; Futian Liu; Liang Xia; Dekang Nie; Feihui Zou; Jinlong Shi; Shaoqing Ju; Longxiang Zhao; Hao Zuo; Jing Qi; Wei Shi
Journal:  J Mol Neurosci       Date:  2013-05-10       Impact factor: 3.444

7.  DNA methylation profiles in African American prostate cancer patients in relation to disease progression.

Authors:  Rohina Rubicz; Shanshan Zhao; Milan Geybels; Jonathan L Wright; Suzanne Kolb; Brandy Klotzle; Marina Bibikova; Dean Troyer; Raymond Lance; Elaine A Ostrander; Ziding Feng; Jian-Bing Fan; Janet L Stanford
Journal:  Genomics       Date:  2016-02-21       Impact factor: 5.736

8.  Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model.

Authors:  Shannon R Morey Kinney; Dominic J Smiraglia; Smitha R James; Michael T Moser; Barbara A Foster; Adam R Karpf
Journal:  Mol Cancer Res       Date:  2008-07-30       Impact factor: 5.852

Review 9.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

10.  LINE-1 family member GCRG123 gene is up-regulated in human gastric signet-ring cell carcinoma.

Authors:  Gang-Shi Wang; Meng-Wei Wang; Ben-Yan Wu; Xin-Yan Yang; Wei-Hua Wang; Wei-Di You
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.